Overview

* ANI Pharmaceuticals ( ANIP ) Q2 net revenues rise 53.1% yr/yr to $211.4 mln

* Adjusted EPS for Q2 beats consensus, reaching $1.80, per LSEG data

* Company raises 2025 guidance, expecting higher net revenues and EPS

Outlook

* Company expects 2025 net revenues of $818 mln to $843 mln

* ANI Pharmaceuticals ( ANIP ) sees 2025 adjusted EBITDA of $213 mln to $223 mln

* Company anticipates Rare Disease revenues to be 57% of total in H2 2025

* ANI forecasts 2025 non-GAAP EPS of $6.98 to $7.35

Result Drivers

* RARE DISEASE GROWTH - Cortrophin Gel net revenues increased 66% yr/yr, driven by higher prescription demand and new patient starts

* GENERIC LAUNCHES - Generics revenues rose 22.1% yr/yr, fueled by new product launches and operational excellence

* OPHTHALMOLOGY EXPANSION - Enhanced sales team and marketing efforts boosted ophthalmology segment, contributing to revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $103.96 $190.30

Revenue mln mln (8

Analysts

)

Q2 Beat $1.8 $1.42 (8

Adjusted Analysts

EPS )

Q2 Net $8.10

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for ANI Pharmaceuticals Inc ( ANIP ) is $84.00, about 17.8% above its August 7 closing price of $69.01

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)